Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TRACON Pharmaceuticals, Inc. (TCON)
OTHER OTC:TCON
Holding TCON?
Track your performance easily
TCON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range<$0.01 - $14.74
Previous Close$0.06
Volume2.77K
Average Volume (3M)74.39K
Market Cap
$187.42K
Enterprise Value-$6.08M
Total Cash (Recent Filing)$6.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)<0.1
Beta1.77
Next Earnings
Nov 06, 2024EPS EstimateN/A
Last Dividend Ex-Date
Jun 27, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)3.79
Shares Outstanding3,407,564
10 Day Avg. Volume8,705
30 Day Avg. Volume74,394
Standard Deviation0.42
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-0.06
Price to Sales (P/S)0.06
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.90
Enterprise Value/Gross Profit-0.50
Enterprise Value/Ebitda-3.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
TRACON Pharmaceuticals News
PremiumCompany Announcements
TRACON Pharmaceuticals Initiates Wind-Down and Leadership Changes
PremiumCompany Announcements
TRACON Pharmaceuticals Announces Executive Officer ResignationBulls Say, Bears Say
Bulls Say
Clinical TrialsThe ongoing P2 pivotal ENVASARC trial has made considerable progress with enrollment complete and updated response data along with a positive IDMC review.
Product DevelopmentTRACON’s product development platform is designed to transform companies’ clinical operations and provide cost savings versus a typical contract research organization.
Study EndpointThe primary endpoint for the study is an objective response rate (ORR) with a minimum efficacy threshold required to statistically exceed the FDA-approved treatment for refractory UPS/MFS.
Bears Say
Clinical TrialsENVASARC trial missed primary endpoint.
Company StrategyTRACON announced that it will discontinue all of the company’s clinical development activities and will focus on reducing cash burn.
Financial PerformanceThe price target is being reduced to $6 from $20 due to expectations of additional dilution associated with future capital raises.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TCON FAQ
What was TRACON Pharmaceuticals, Inc.’s price range in the past 12 months?
TRACON Pharmaceuticals, Inc. lowest stock price was <$0.01 and its highest was $14.74 in the past 12 months.
What is TRACON Pharmaceuticals, Inc.’s market cap?
Currently, no data Available
When is TRACON Pharmaceuticals, Inc.’s upcoming earnings report date?
TRACON Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were TRACON Pharmaceuticals, Inc.’s earnings last quarter?
TRACON Pharmaceuticals, Inc. released its earnings results on Aug 07, 2024. The company reported -$0.944 earnings per share for the quarter, beating the consensus estimate of -$1.05 by $0.106.
Is TRACON Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts TRACON Pharmaceuticals, Inc.’s price is currently Overvalued.
Does TRACON Pharmaceuticals, Inc. pay dividends?
TRACON Pharmaceuticals, Inc. pays a Notavailable dividend of $0.04 which represents an annual dividend yield of N/A. See more information on TRACON Pharmaceuticals, Inc. dividends here
What is TRACON Pharmaceuticals, Inc.’s EPS estimate?
TRACON Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TRACON Pharmaceuticals, Inc. have?
TRACON Pharmaceuticals, Inc. has 3,407,564 shares outstanding.
What happened to TRACON Pharmaceuticals, Inc.’s price movement after its last earnings report?
TRACON Pharmaceuticals, Inc. reported an EPS of -$0.944 in its last earnings report, beating expectations of -$1.05. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of TRACON Pharmaceuticals, Inc.?
Among the largest hedge funds holding TRACON Pharmaceuticals, Inc.’s share is ETF Portfolio Partners, Inc.. It holds TRACON Pharmaceuticals, Inc.’s shares valued at N/A.
---
TRACON Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
TCON Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▼ 11.7%
Last 30 Days ▼ 11.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.29%
Trailing 12-Months
Company Description
TRACON Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
---
TCON Earnings Call
Q1 2024
0:00 / 0:00
---
TCON Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering TCON
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-92.40%
reiterated a buy rating 4 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -92.40% per trade.
---